Indeed, the BRCA-mutated BC exhibits specific clinical characteristics, such as increased sensitivity to PARPi, DNA-damaging agents such as platinum-based chemotherapies, and potentially decreased sensitivity to CDK4/6 inhibitors. Here, CDK4 is linked to breast cancer.